<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/D9F3221F-DA1C-46C3-852C-C197E35E23E0/chart/price-vs-fair-value?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/D9F3221F-DA1C-46C3-852C-C197E35E23E0/chart/price-vs-fair-value"/></p>
<p>納斯達克：IRWD 1 年股價與公允價值對比</p>
<p>探索來自社區的 Ironwood Pharmaceuticals 公允價值並選擇您的觀點</p>
<p>上週，Ironwood Pharmaceuticals, Inc.（納斯達克：IRWD）的股票上漲了 15%，但在過去一年中出售了價值 51.5 萬美元股票的內部人士可能處於更有利的位置。以每股 1.78 美元的平均價格出售，超過當前價格，可能是明智的選擇，因為持有股票意味着他們的投資現在的價值低於出售時的價值。</p>
<p>雖然我們絕不會建議投資者僅僅根據公司董事的行為來做出決策，但邏輯上你應該關注內部人士是否在買入或賣出股票。</p>
<p>特朗普承諾要 “釋放” 美國的石油和天然氣，這 15 只美國股票的發展有望受益。</p>
<h2>Ironwood Pharmaceuticals 過去 12 個月的內部交易</h2>
<p>在過去一年中，我們看到最大的內部出售是首席執行官兼董事 Thomas McCourt 以約 245,000 美元的股份出售，價格約為每股 1.76 美元。我們通常不喜歡看到內部人士出售，但出售價格越低，我們越擔心。好的一面是，這次出售發生在最新價格（1.03 美元）之上。因此，很難從中得出任何強有力的結論。</p>
<p>Ironwood Pharmaceuticals 的內部人士在過去一年中沒有購買任何股票。您可以在下面的圖表中看到過去一年內部交易（由公司和個人進行）的情況。點擊下面的圖表，您可以查看每筆內部交易的詳細信息！</p>
<p>查看我們對 Ironwood Pharmaceuticals 的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/31498-insider-trading-volume-1-dark-2/1755432725239?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/31498-insider-trading-volume-1-dark-2/1755432725239"/></p>
<p>納斯達克：IRWD 內部交易量 2025 年 8 月 17 日</p>
<p>如果您和我一樣，那麼您 <strong>不</strong> 會想錯過這份 <strong>免費的</strong> 小型股名單，這些股票不僅被內部人士購買，而且估值也很有吸引力。</p>
<h2>Ironwood Pharmaceuticals 的內部人士最近出售了股票</h2>
<p>在過去三個月中，我們看到 Ironwood Pharmaceuticals 有一些內部人士出售股票。在此期間，內部人士僅出售了價值 11,000 美元的股份。看到內部人士出售股票以及缺乏近期買家的情況並不好。但出售的規模並不足以作為有用的信號。</p>
<h2>Ironwood Pharmaceuticals 是否擁有高比例的內部持股？</h2>
<p>查看公司內部人士的總持股可以幫助您瞭解他們是否與普通股東的利益一致。高比例的內部持股通常使公司領導層更加關注股東的利益。從我們的數據來看，內部人士持有價值 400 萬美元的 Ironwood Pharmaceuticals 股票，約佔公司 2.4%。我們更傾向於看到高比例的內部持股。</p>
<h2>Ironwood Pharmaceuticals 的內部交易可能告訴我們什麼？</h2>
<p>在過去三個月中，我們沒有看到任何內部人士買入，但我們確實看到了出售。但出售規模較小，因此我們並不擔心。我們對 Ironwood Pharmaceuticals 的內部出售持謹慎態度。根據我們的數據，通常內部人士在公司中擁有更多股票。因此，這些內部交易可以幫助我們建立對該股票的看法，但瞭解該公司面臨的風險也是值得的。每家公司都有風險，我們已經發現了 <strong>3 個警告信號</strong>，您應該瞭解 Ironwood Pharmaceuticals。</p>
<p>當然，<strong>您可能會通過尋找其他地方找到一個絕佳的投資機會。</strong> 所以請查看這份 <strong>免費的</strong> 有趣公司名單。</p>
<p><em>在本文中，內部人士是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置，但不包括衍生交易或間接利益。</em></p>

Ironwood醫藥

<p>Ironwood Pharma（NASDAQ:IRWD）上週股價上漲了 15%，但內部人士在過去一年內出售了價值 51.5 萬美元的股票，其中首席執行官 Thomas McCourt 的最大出售額為 24.5 萬美元。儘管有出售，但平均出售價格高於當前價格 1.03 美元。內部人士持有公司約 2.4% 的股份，儘管有一些出售，但並不足以引發重大擔憂。投資者應保持謹慎，並考慮與公司相關的風險</p>

<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/D9F3221F-DA1C-46C3-852C-C197E35E23E0/chart/price-vs-fair-value" alt="" original-src="https://images.simplywall.st/company/D9F3221F-DA1C-46C3-852C-C197E35E23E0/chart/price-vs-fair-value"/></p>
<p>NasdaqGS:IRWD 1 Year Share Price vs Fair Value</p>
<div class="lb-trans"><p>納斯達克：IRWD 1 年股價與公允價值對比</p>
</div><p>Explore Ironwood Pharmaceuticals's Fair Values from the Community and select yours</p>
<div class="lb-trans"><p>探索來自社區的 Ironwood Pharmaceuticals 公允價值並選擇您的觀點</p>
</div><p>Last week, Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) stock jumped 15%, but insiders who sold US$515k worth of stock in over the past year are likely to be in a better position. Selling at an average price of US$1.78, which is higher than the current price might have been the right call as holding on to stock would have meant their investment would be worth less now than it was at the time of sale.</p>
<div class="lb-trans"><p>上週，Ironwood Pharmaceuticals, Inc.（納斯達克：IRWD）的股票上漲了 15%，但在過去一年中出售了價值 51.5 萬美元股票的內部人士可能處於更有利的位置。以每股 1.78 美元的平均價格出售，超過當前價格，可能是明智的選擇，因為持有股票意味着他們的投資現在的價值低於出售時的價值。</p>
</div><p>While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, logic dictates you should pay some attention to whether insiders are buying or selling shares.</p>
<div class="lb-trans"><p>雖然我們絕不會建議投資者僅僅根據公司董事的行為來做出決策，但邏輯上你應該關注內部人士是否在買入或賣出股票。</p>
</div><p>Trump has pledged to &#34;unleash&#34; American oil and gas and these 15 US stocks have developments that are poised to benefit.</p>
<div class="lb-trans"><p>特朗普承諾要 “釋放” 美國的石油和天然氣，這 15 只美國股票的發展有望受益。</p>
</div><h2>The Last 12 Months Of Insider Transactions At Ironwood Pharmaceuticals</h2>
<div class="lb-trans"><h2>Ironwood Pharmaceuticals 過去 12 個月的內部交易</h2>
</div><p>Over the last year, we can see that the biggest insider sale was by the CEO &amp; Director, Thomas McCourt, for US$245k worth of shares, at about US$1.76 per share. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. The silver lining is that this sell-down took place above the latest price (US$1.03). So it is hard to draw any strong conclusion from it.</p>
<div class="lb-trans"><p>在過去一年中，我們看到最大的內部出售是首席執行官兼董事 Thomas McCourt 以約 245,000 美元的股份出售，價格約為每股 1.76 美元。我們通常不喜歡看到內部人士出售，但出售價格越低，我們越擔心。好的一面是，這次出售發生在最新價格（1.03 美元）之上。因此，很難從中得出任何強有力的結論。</p>
</div><p>Ironwood Pharmaceuticals insiders didn't buy any shares over the last year. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!</p>
<div class="lb-trans"><p>Ironwood Pharmaceuticals 的內部人士在過去一年中沒有購買任何股票。您可以在下面的圖表中看到過去一年內部交易（由公司和個人進行）的情況。點擊下面的圖表，您可以查看每筆內部交易的詳細信息！</p>
</div><p>Check out our latest analysis for Ironwood Pharmaceuticals</p>
<div class="lb-trans"><p>查看我們對 Ironwood Pharmaceuticals 的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/31498-insider-trading-volume-1-dark-2/1755432725239" alt="" original-src="https://images.simplywall.st/asset/chart/31498-insider-trading-volume-1-dark-2/1755432725239"/></p>
<p>NasdaqGS:IRWD Insider Trading Volume August 17th 2025</p>
<div class="lb-trans"><p>納斯達克：IRWD 內部交易量 2025 年 8 月 17 日</p>
</div><p>If you are like me, then you will <strong>not</strong> want to miss this <strong>free</strong> list of small cap stocks that are not only being bought by insiders but also have attractive valuations.</p>
<div class="lb-trans"><p>如果您和我一樣，那麼您 <strong>不</strong> 會想錯過這份 <strong>免費的</strong> 小型股名單，這些股票不僅被內部人士購買，而且估值也很有吸引力。</p>
</div><h2>Insiders At Ironwood Pharmaceuticals Have Sold Stock Recently</h2>
<div class="lb-trans"><h2>Ironwood Pharmaceuticals 的內部人士最近出售了股票</h2>
</div><p>We have seen a bit of insider selling at Ironwood Pharmaceuticals, over the last three months. Insiders sold just US$11k worth of shares in that time. It's not great to see insider selling, nor the lack of recent buyers. But the selling simply isn't sufficiently substantial to be of much use as a signal.</p>
<div class="lb-trans"><p>在過去三個月中，我們看到 Ironwood Pharmaceuticals 有一些內部人士出售股票。在此期間，內部人士僅出售了價值 11,000 美元的股份。看到內部人士出售股票以及缺乏近期買家的情況並不好。但出售的規模並不足以作為有用的信號。</p>
</div><h2>Does Ironwood Pharmaceuticals Boast High Insider Ownership?</h2>
<div class="lb-trans"><h2>Ironwood Pharmaceuticals 是否擁有高比例的內部持股？</h2>
</div><p>Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. A high insider ownership often makes company leadership more mindful of shareholder interests. From looking at our data, insiders own US$4.0m worth of Ironwood Pharmaceuticals stock, about 2.4% of the company. We prefer to see high levels of insider ownership.</p>
<div class="lb-trans"><p>查看公司內部人士的總持股可以幫助您瞭解他們是否與普通股東的利益一致。高比例的內部持股通常使公司領導層更加關注股東的利益。從我們的數據來看，內部人士持有價值 400 萬美元的 Ironwood Pharmaceuticals 股票，約佔公司 2.4%。我們更傾向於看到高比例的內部持股。</p>
</div><h2>What Might The Insider Transactions At Ironwood Pharmaceuticals Tell Us?</h2>
<div class="lb-trans"><h2>Ironwood Pharmaceuticals 的內部交易可能告訴我們什麼？</h2>
</div><p>We did not see any insider buying in the last three months, but we did see selling. But the sales were small, so we're not concerned. We're a little cautious about the insider selling at Ironwood Pharmaceuticals. And usually insiders own more stock in the company, according to our data. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. Every company has risks, and we've spotted <strong>3 warning signs for Ironwood Pharmaceuticals</strong> you should know about.</p>
<div class="lb-trans"><p>在過去三個月中，我們沒有看到任何內部人士買入，但我們確實看到了出售。但出售規模較小，因此我們並不擔心。我們對 Ironwood Pharmaceuticals 的內部出售持謹慎態度。根據我們的數據，通常內部人士在公司中擁有更多股票。因此，這些內部交易可以幫助我們建立對該股票的看法，但瞭解該公司面臨的風險也是值得的。每家公司都有風險，我們已經發現了 <strong>3 個警告信號</strong>，您應該瞭解 Ironwood Pharmaceuticals。</p>
</div><p>Of course, <strong>you might find a fantastic investment by looking elsewhere.</strong> So take a peek at this <strong>free</strong> list of interesting companies.</p>
<div class="lb-trans"><p>當然，<strong>您可能會通過尋找其他地方找到一個絕佳的投資機會。</strong> 所以請查看這份 <strong>免費的</strong> 有趣公司名單。</p>
</div><p><em>For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.</em></p>
<div class="lb-trans"><p><em>在本文中，內部人士是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置，但不包括衍生交易或間接利益。</em></p>
</div>

隨着內部人士出售股票金額達到 51.5 萬美元，需密切關注 Ironwood Pharmaceuticals